Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AIFF
Upturn stock ratingUpturn stock rating

Firefly Neuroscience, Inc. (AIFF)

Upturn stock ratingUpturn stock rating
$2.64
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: AIFF (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -87.36%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 38.84M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 1.86 - 17.20
Updated Date 06/16/2025
52 Weeks Range 1.86 - 17.20
Updated Date 06/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.12

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -4802.33%

Management Effectiveness

Return on Assets (TTM) -86.34%
Return on Equity (TTM) -860.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 37724522
Price to Sales(TTM) 279.43
Enterprise Value 37724522
Price to Sales(TTM) 279.43
Enterprise Value to Revenue 271.4
Enterprise Value to EBITDA -
Shares Outstanding 12861100
Shares Floating 8202680
Shares Outstanding 12861100
Shares Floating 8202680
Percent Insiders 40.48
Percent Institutions 9.56

ai summary icon Upturn AI SWOT

Firefly Neuroscience, Inc.

stock logo

Company Overview

overview logo History and Background

Firefly Neuroscience, Inc. is a neurotechnology company focused on advancing brain health assessment through EEG-based solutions. Founded in 2015, the company has developed technology aimed at providing objective, quantitative insights into brain function to aid in the diagnosis and treatment of neurological and psychiatric disorders.

business area logo Core Business Areas

  • Clinical EEG Analysis: Provides EEG-based solutions for clinicians to aid in diagnosing neurological and psychiatric conditions.
  • Pharmaceutical Research: Partners with pharmaceutical companies to utilize EEG data in clinical trials for drug development and personalized medicine.
  • Digital Health: Developing digital health solutions to assess and monitor brain health through EEG data.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the medical device and pharmaceutical industries. The organizational structure is designed to facilitate innovation and commercialization of its EEG technology.

Top Products and Market Share

overview logo Key Offerings

  • Firefly Brain Network Analysis (BNA): Proprietary EEG analysis platform providing objective metrics of brain function. The market share is still developing. Competitors include companies offering quantitative EEG analysis, such as NeuroGuide and BrainScope.

Market Dynamics

industry overview logo Industry Overview

The neurotechnology market is growing, driven by increasing awareness of brain health and advancements in EEG technology. There's growing demand for objective measures of brain function in the diagnosis and treatment of neurological and psychiatric disorders.

Positioning

Firefly Neuroscience positions itself as a leader in quantitative EEG analysis, with its BNA platform providing advanced insights into brain function. The company aims to improve diagnostic accuracy and treatment outcomes in neurological and psychiatric care.

Total Addressable Market (TAM)

The estimated total addressable market for brain health and diagnostics is in the billions of dollars. Firefly Neuroscience is positioned to capture a significant portion of this market by offering innovative EEG-based solutions.

Upturn SWOT Analysis

Strengths

  • Proprietary EEG analysis platform
  • Experienced leadership team
  • Partnerships with pharmaceutical companies
  • Focus on objective brain function measurement

Weaknesses

  • Limited market penetration
  • Requires regulatory approvals for some applications
  • Dependent on research and development
  • Small company size in comparison to competitors

Opportunities

  • Expanding partnerships with healthcare providers
  • Development of new EEG-based applications
  • Increasing adoption of digital health solutions
  • Growing demand for objective brain function assessment

Threats

  • Competition from established neurotechnology companies
  • Regulatory hurdles
  • Reimbursement challenges
  • Technological advancements by competitors

Competitors and Market Share

competitor logo Key Competitors

  • ANTM
  • EBSO

Competitive Landscape

Firefly Neuroscience differentiates itself through its proprietary EEG analysis platform and focus on objective brain function measurement. Its smaller size and limited market penetration are disadvantages compared to larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is difficult to determine without financials. The company is focused on growth.

Future Projections: Future projections are unavailable, depends on securing contracts.

Recent Initiatives: Recent initiatives include expanding partnerships with healthcare providers and pharmaceutical companies, as well as developing new EEG-based applications.

Summary

Firefly Neuroscience is an early-stage neurotechnology company with a promising EEG analysis platform. Securing strategic partnerships and increasing market penetration will be crucial for its success. It needs to closely monitor competition and adapt to changing market dynamics to capitalize on opportunities in the growing brain health market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • Industry reports
  • Market research reports

Disclaimers:

The information provided is for informational purposes only and should not be considered as investment advice. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Firefly Neuroscience, Inc.

Exchange NASDAQ
Headquaters Kenmore, NY, United States
IPO Launch date 2011-02-23
CEO & Director Mr. Greg Lipschitz
Sector Technology
Industry Software - Application
Full time employees 13
Full time employees 13

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.